Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, PK, and PD of Single Ascending Doses of KN-002 in Healthy Subjects and Multiple Ascending Doses of KN-002 in Subjects With Mild Asthma, Moderate-Severe Asthma and COPD

NCT05006521 is registered in ClinicalTrials.gov with Kinaset Therapeutics Inc as lead sponsor.

NCT NCT05006521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05006521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, PK, and PD of Single Ascending Doses of KN-002 in Healthy Subjects and Multiple Ascending Doses of KN-002 in Subjects With Mild Asthma, Moderate-Severe Asthma and COPD
Lead sponsor
Kinaset Therapeutics Inc
Phase
Phase 1
Overall status
Completed
Start date
July 30, 2021
Completion date
July 25, 2024
Enrollment
117 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma copd